Skip to content
Clinical Trials – home

University Hospital Cologne

Verified siteinfo

Germany Kerpener Strasse 62, Lindenthal, 50937 Cologne, Germany

  • 195 trials recruiting
  • Non-small cell lung cancer · Chronic lymphocytic leukaemia · Plasma cell myeloma
  • Adults and children

About Specializations

University Hospital Cologne in Cologne, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Chronic lymphocytic leukaemia, Plasma cell myeloma, Systemic lupus erythematosus, and other specialisations. This site conducts important research.

Main research areas of the site

Eye Diseases at University Hospital Cologne

Clinical research in ophthalmology focuses on geographic atrophy secondary to age-related macular degeneration, with studies designed to explore whether new treatments can slow disease progression and protect vision.

  • Evaluating potential therapies for geographic atrophy linked to age-related macular degeneration
  • Assessing the effect of new approaches on lesion growth and eye disease progression
  • Improving treatment options for advanced retinal disease

These trials aim to support better care for people facing progressive vision loss and to expand the range of available eye disease treatments.

Hemic and Lymphatic Diseases

The hematology research program includes studies in immune-mediated thrombotic thrombocytopenic purpura and related thrombotic microangiopathy conditions, with a focus on improving safety and treatment effectiveness in acute care settings.

  • Testing new treatment options for immune-mediated thrombotic thrombocytopenic purpura
  • Studying therapies for thrombotic microangiopathy and closely related blood disorders
  • Evaluating how well emerging treatments are tolerated in urgent clinical situations

This work at University Hospital Cologne supports efforts to improve outcomes in rare but serious blood disorders.

Psychiatry and Psychology

In mental health research, the site is studying schizophrenia, with trials aimed at understanding whether new therapies can improve cognitive function and daily functioning for adults living with the condition.

  • Assessing treatments intended to improve cognitive impairment in schizophrenia
  • Exploring better ways to support thinking and memory symptoms
  • Evaluating the overall usefulness of new psychiatric therapies

These studies reflect a broader effort to advance care in psychiatry by addressing both symptoms and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Kerpener Strasse 62, Lindenthal50937 CologneGermany
Recruiting now
195 trials
Conditions studied
281
Partner status
Verified site

More sites in CologneGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

461 clinical trials

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:University Of Cologne

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.